Laurus Labs’ distribution partner Rising Pharmaceuticals launches Pregabalin Capsules in US market
Pregabalin Capsules and had US sales of approximately $5,497 million for the 12 months ending March 2019, according to IMS Health
Laurus Labs along with its exclusive distribution partner Rising Pharmaceuticals announced the launch of the generic version of Lyrica, (pregabalin) Capsules, in all eight commercially available strengths (25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg, & 300 mg) in US market. Rising recently received the final approval from the US Food and Drug Administration (FDA) for the Abbreviated New Drug Application (ANDA).
Pregabalin Capsules are indicated for management of neuropathic pain associated with diabetic peripheral neuropathy, for the management of postherpetic neuralgia, for adjunctive therapy for the treatment of partial onset seizures in patients four years of age and older, for the management of fibromyalgia, and for the management of neuropathic pain associated with spinal cord injury. The product should be taken only as prescribed. Pregabalin Capsules and had US sales of approximately $5,497 million for the 12 months ending March 2019, according to IMS Health.
“Laurus Labs is a fully integrated pharmaceutical company, backed by the state of the art manufacturing facilities in Visakhapatnam, Andhra Pradesh. We are happy to develop and manufacture the Pregabalin capsules for our exclusive distribution partner Rising Pharmaceuticals in US. Currently we have five billion units per year capacity which can be expanded to eight billion units per year based on the demand. As we move forward in the segment backed by our strong API manufacturing facilities, with strategic partnerships in place, we will strengthen our portfolio for driving long-term, sustainable growth by leveraging our partnerships and global presence,” said Dr Satyanarayana Chava, Founder & CEO, Laurus Labs.
“The commercialization of Pregabalin Capsules is one of the largest volume launches for the company this year and will provide a cost effective treatment option for people living with debilitating neuropathic pain conditions,” said Vimal Kavuru, Chief Executive Officer for Rising Pharmaceuticals.
Rising Pharmaceuticals sells generic prescription products and over-the-counter pharmaceutical products under the Rising label to leading wholesalers, chain drug stores, distributors and mass merchandisers.